Kumovis got its start at the Technical University of Munich by five alumni in fields ranging from medical technology to polymer engineering. They co-founded the company focusing on 3D printing medical devices with high-performance and biodegradable polymers. Just two years later, in 2019, Kumovis released the R1 3D printer introducing a system for decentralized clean room production to the medtech market.
The company delivers a range of products and services, including 3D printer installations, on-site trainings and medical product design, among others. Kumovis enables additive manufactured individualized implants and small batches of surgical instruments with filaments such as PEEK, PPSU and PLA in a reproducible and regulatory compliant way — whenever and wherever healthcare workers need them.
As Kumovis, we create leading-edge technologies to ensure outstanding patient care.
We enable the creation of medical products that bring outstanding benefits to the healthcare sector and especially its patients. Driven by their needs, we create new technologies, develop sound processes and provide materials.
Together with our partners, we build and establish an ecosystem, that has our 3D printing knowledge and technology at its core. With everything we do, we exceed medical technology requirements and regulations.
The values we share
People, especially their personality and well-being, are the most valuable to us as Kumovis. We are open and respectful, and we care for each other. This is the basis of working together and building up trusting relationships – inside our team, with our partners and our customers. The motivation we have as an organization is continuously inspired by the passion of every single individual. This is what makes working together a lot of fun.
IMPACT THROUGH INNOVATION
At Kumovis, we live a culture that fosters our creativity, encourages us to try out new things and think outside of the box. We apply our strong research-based background and our mentality to think two steps ahead in order to solve complex problems.
Together with our interdisciplinary partners, we co-create a full solution for medical 3D printing. We believe that building up close co-operation and trustful partnerships with other experts is essential to solve today’s challenges of the healthcare sector.
We are aware of the impact our work has on the well-being of patients who are treated using our technologies and services. To value this great responsibility, it is natural for us to fulfil the high requirements when building products that are applied in the medical industry.
At Kumovis, we always strive for the highest quality and reliability of our products and services. Finding the path between a high degree of innovation and meeting the requirements of the medical industry is a challenge we tackle with passion every day.
A brief history of Kumovis
Kumovis builds ist first Proof of Concept PEEK 3D printer and receives positive feedback from various industry experts7. July 2020
Kumovis is founded in Munich with the goal to offer a groundbreaking 3D-printer for medical high-performance polymers7. July 2020
Kumovis receives a Seed funding of 1.2 Million € to continue development of the its 3D-printing system7. July 2020
Kumovis can deliver its first Pre-Series printer HTRD to various customers7. July 2020
Kumovis launches its first series product, the KUMOVIS R1 and starts shipping to the first customer7. July 2020
Kumovis receives funding of 3.6 Million € in a Series A round from several investors7. July 2020
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge almost 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital business models, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected over EUR 2.5 billion into the HTGF portfolio via more than 1,600 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies.
Investors in the public-private partnership include the Federal Ministry of Economics and Energy, KfW Capital, the Fraunhofer-Gesellschaft and 32 companies.
SOLVAY VENTURES is the Venture Capital fund of Solvay, investing in breakthrough technologies in advanced materials and formulations. Operating since 2005, Solvay Ventures currently invests out of a €80m global evergreen fund. Solvay Ventures targets early stage investment opportunities (Seed through Series B) with a focus on startups solving problems in sustainable resources, energy transition, increased wellbeing, and digital age. Beyond capital, Solvay Ventures leverages the resources at Solvay to accelerate technology and market adoption.
The RENOLIT Group is a globally active specialist for high performance polymer films, sheets and other plastic products. With more than thirty sites and sales units in over twenty countries, and with annual sales of EUR 1.059 billion in fiscal year 2019, the company with headquarters in Worms – around 70 km South of Frankfurt-am-Main – is one of the world’s leading plastics product manufacturers. More than 4,800 employees continue to further develop the knowledge and expertise gained from over seventy years of business.
Advanced medical technology thanks to additive manufacturing
Sign up for our newsletter, and we will keep you posted about the latest developments and trends in medical 3D printing.